Injection with methylprednisolone proximal to the carpal tunnel: randomised double blind trial
Dammers, J.W.H.H.; Veering, M.M.; Vermeulen, M.

Published in:
BMJ : British medical journal

Citation for published version (APA):
Injection with methylprednisolone proximal to the carpal tunnel: randomised double blind trial
J W H H Dammers, M M Veering and M Vermeulen

BMJ 1999;319;884-886

Updated information and services can be found at:
http://bmj.com/cgi/content/full/319/7214/884

These include:

References
This article cites 8 articles, 2 of which can be accessed free at:
http://bmj.com/cgi/content/full/319/7214/884#BIBL

15 online articles that cite this article can be accessed at:
http://bmj.com/cgi/content/full/319/7214/884#otherarticles

Rapid responses
10 rapid responses have been posted to this article, which you can access for free at:
http://bmj.com/cgi/content/full/319/7214/884#responses

You can respond to this article at:
http://bmj.com/cgi/eletter-submit/319/7214/884

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections

Other Rheumatology (1698 articles)

Notes

To order reprints of this article go to:
http://www.bmjournals.com/cgi/reprintform

To subscribe to BMJ go to:
http://bmj.bmjjournals.com/subscriptions/subscribe.shtml
Abstract

Objective To assess the effect of a 40 mg methylprednisolone injection proximal to the carpal tunnel in patients with the carpal tunnel syndrome.

Design Randomised double blind placebo controlled trial.

Setting Outpatient neurology clinic in a district general hospital.

Participants Patients with symptoms of the carpal tunnel syndrome for more than 3 months, confirmed by electrophysiological tests and aged over 18 years.

Intervention Injection with methylprednisolone (lidocaine) or 10 mg lignocaine and 40 mg methylprednisolone. Non-responders who had received lignocaine received 40 mg methylprednisolone and 10 mg lignocaine and were followed in an open study.

Main outcome measures Participants were scored as having improved or not improved. Improved was defined as no symptoms or minor symptoms requiring no further treatment.

Results At 1 month 6 (20%) of 30 patients in the control group had improved compared with 23 (77%) of 30 patients the intervention group (difference 57% (95% confidence interval 36% to 77%). After 1 year, 2 of 6 improved patients in the control group did not need a second treatment, compared with 15 of 23 improved patients in the intervention group (difference 43% (23%) to 63%). Of the 28 non-responders in the control group, 24 (86%) improved after methylprednisolone. Of these 24 patients, 12 needed surgical treatment within one year.

Conclusion A single injection with steroids close to the carpal tunnel may result in long term improvement and should be considered before surgical decompression.

Introduction

The carpal tunnel syndrome is caused by compression of the median nerve at the wrist and is a common cause of pain in the arm, particularly in women. Injection with corticosteroids is one of the many recommended treatments.1

One of the techniques for such injection entails injection just proximal to (not into) the carpal tunnel. The rationale for this injection site is that there is often a swelling at the volar side of the forearm, close to the carpal tunnel, which might contribute to compression of the median nerve. Moreover, the risk of damaging the median nerve by injection at this site is lower than by injection into the narrow carpal tunnel. The rationale for using lignocaine (lidocaine) together with corticosteroids is twofold: the injection is painless, and diminished sensation afterwards shows that the injection was properly carried out.

We investigated in a double blind randomised trial, firstly, whether symptoms disappeared after injection with corticosteroids proximal to the carpal tunnel and, secondly, how many patients remained free of symptoms at follow up after this treatment.

Participants and methods

Participants

The participants were patients referred to the Medical Centre Alkmaar with signs and symptoms of the carpal tunnel syndrome of more than 3 months’ duration confirmed by electrophysiological tests. In those with bilateral symptoms, the arm with the most severe symptoms was chosen, and treatment of this arm was randomised. We excluded patients aged under 18 years or patients who had already been treated for symptoms of the carpal tunnel syndrome.
The trial was approved by the medical centre's ethics committee. Patients gave written informed consent. The ethics committee required an interim analysis after inclusion of half of all participants.

**Intervention**

The injections were given by one neurologist (JWHHD). They contained 10 mg lignocaine or 10 mg lignocaine and 40 mg methylprednisolone. The site of injection was at the volar side of the forearm 4 cm proximal to the wrist crease between the tendons of the radial flexor muscle and the long palmar muscle. Injections were given with a 3 cm long (0.7 mm needle fig 1). The angle of introduction of the needle depended on the size of the wrist. In participants with a thin wrist the median nerve is close to the skin. In these participants the angle was 10°. The angle was larger, about 20°, in those with a thick wrist. In participants with well developed muscles, the pronator quadratus muscle may push up the median nerve, so in a thick muscular arm the angle of introduction was also flat, between 10° and 20°. The needle was introduced slowly, and the participant was instructed to say stop if he or she felt pins and needles or pain in the fingers. If a resistance was felt the needle was withdrawn a few millimetres then repositioned. The injection was given without much pressure. After injection, the 1 ml fluid bolus was gently massaged towards the carpal tunnel.

**Outcome**

One month after injection the randomised participants visited the outpatient department and were asked by another neurologist (MMV) whether they had no symptoms or only minor symptoms that they considered so much improved that they felt no further treatment was necessary. Further visits were planned for 3, 6, 9, and 12 months after the injection or earlier if the participant felt this was necessary. At these visits, participants were asked the same question. If treatment was necessary the decision to treat was taken first, and then the trial code was broken. If a patient had not been treated with methylprednisolone this treatment was offered, otherwise surgical decompression was performed.

**Assignment and blinding**

Using a random number table, the hospital pharmacist prepared the trial drug in blocks of 20. The syringes for injection were sent from the pharmacy to the outpatient department, where it was impossible to distinguish the syringes containing methylprednisolone plus lignocaine from those containing lignocaine as paper was glued around the syringes. To further ensure blinding, the assessments were carried out by another neurologist (MMV). Neither the doctor nor the participant, therefore, knew what treatment was given. The doctors and participants remained blind to treatment during the assessments at follow up.

**Sample size**

The sample size calculation was based on the assumption that after 1 month 80% of the participants in the intervention group would respond to treatment versus 50% in the control group. With a power of 80% and a significance level of 5% two sided, this meant that at least 80 participants needed to be included.

---

**Table 1** Baseline characteristics of 60 participants in trial

<table>
<thead>
<tr>
<th>Variable</th>
<th>Intervention</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of participants</td>
<td>30</td>
<td>30</td>
</tr>
<tr>
<td>Mean age (years)</td>
<td>53</td>
<td>51</td>
</tr>
<tr>
<td>No of females</td>
<td>24</td>
<td>26</td>
</tr>
<tr>
<td>No of patients with pain in arm at night</td>
<td>27</td>
<td>26</td>
</tr>
<tr>
<td>No of patients with swelling near carpal tunnel</td>
<td>19</td>
<td>26</td>
</tr>
<tr>
<td>Average duration of symptoms (months)</td>
<td>32</td>
<td>25</td>
</tr>
</tbody>
</table>

**Table 2** Treatment response at follow up

<table>
<thead>
<tr>
<th>Period after treatment</th>
<th>Intervention group (n=30)</th>
<th>Control group (n=30)</th>
<th>% observed difference (95% confidence interval of difference)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 month</td>
<td>23 (77)</td>
<td>6 (20)</td>
<td>57 (36 to 77)</td>
</tr>
<tr>
<td>3 months</td>
<td>19 (63)</td>
<td>2 (7)</td>
<td>56 (37 to 76)</td>
</tr>
<tr>
<td>6 months</td>
<td>17 (57)</td>
<td>2 (7)</td>
<td>50 (30 to 70)</td>
</tr>
<tr>
<td>9 months</td>
<td>16 (53)</td>
<td>2 (7)</td>
<td>46 (27 to 67)</td>
</tr>
<tr>
<td>12 months</td>
<td>15 (50)</td>
<td>2 (7)</td>
<td>43 (23 to 63)</td>
</tr>
</tbody>
</table>

---

**Fig 2** Participant flow

**Analysis**

We used χ² and Fisher’s exact tests to compare differences between the groups. We calculated the 95% confidence intervals of the differences of the proportion of participants who responded to treatment.

**Results**

After the ethics committee had seen the results of the interim analysis (after 40 participants had been recruited) it withdrew permission for further randomisation. Meanwhile a further 20 participants had entered the study. The final analysis of the results is on all 60 randomised patients. None of the participants was lost at follow up. Figure 2 shows the participant flow.

Table 1 shows the baseline characteristics. No significant differences existed between the groups. After 1 month 23 of the 30 participants in the intervention
group had no or only minor symptoms versus 6 of the 30 participants in the control group (P < 0.001). Table 2 shows the proportion of participants not needing a second treatment. At all time intervals the number of participants not requiring treatment was significantly higher in the intervention group.

In the open phase of the study 24 of 28 participants in the control group responded to treatment with methylprednisolone. Of this group, 12 of 24 participants needed a third treatment (surgery), performed on average 3.4 months after the second treatment. There were no side effects.

Discussion

This study confirmed a beneficial effect of injection with methylprednisolone near the carpometacarpal joint. In the center where this study was performed, neurologists have for 20 years been injecting methylprednisolone close to, but not in, the carpal tunnel syndrome. The neurologists claimed not only excellent results in the short term but also long lasting improvements. The duration of improvement shown in this double blind controlled study seemed to be longer than has been reported in other studies.1-4 Two studies were clinical trials.5 6 In the first trial, injections with steroids into the carpal tunnel were compared with intramuscular injections. At the end of 4 months, a significant improvement was seen in the group of 18 patients who had been given injections into the carpal tunnel, but this beneficial effect had disappeared after 10-12 months. In the second trial methylprednisolone was injected locally, and again the effect of treatment was of short duration.

Our rationale for positioning injections close to the carpal tunnel was that injections at this site are less likely to damage the nerve and are easier to carry out than injections into the carpal tunnel. Another reason why this site was chosen was the common occurrence of a swelling close to the carpal tunnel—in this study in three quarters of the participants. Such a swelling probably consists of fat tissue and hyper trophy of the pronator quadratus muscle. A locally applied injection may reduce the swelling by the lipolytic action of methylprednisolone, which would explain the long term beneficial effect. Whether this is true, this treatment is safe and is easier to carry out than surgical decompression or 20 sessions of ultrasound treatment.

We thank J Prins of the hospital's pharmacy for preparing the syringes.

Contributors: JWHHH designed the study, asked for informed consent, randomised the patients, gave the injections, and wrote the first draft of the manuscript. MMV commented on the study design, did the follow up assessments, and commented on the manuscript. MV commented on the study design, analysed the results, and commented on the manuscript. All authors will act as guarantors for this paper.

Funding: None.

Competing interests: None declared.


(Accepted 10 June 1999)